（文章来源：证券日报） 证券日报网讯亨迪药业9月23日在互动平台回答投资者提问时表示，截至2025年9月19日，公司股东户数 为18196户。 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2025-042 湖北亨迪药业股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 1、本次股东大会没有出现否决议案的情况； 2、本次股东大会不涉及变更以往股东大会已通过决议的情况； 3、本次股东大会以现场与网络投票相结合的方式召开。 一、会议召开和出席的情况 （一）会议召开情况 1、会议召开时间： （1）现场会议召开时间：2025 年 9 月 18 日（星期四）下午 14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投 票的具体时间为：2025 年 9 月 18 日上午 9:15-9:25，9:30-11:30， 下午 13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体 时间为：2025 年 8 月 18 日 9:15—15:00 期间的任意时间。 2、会议召开方式：本次股东大会采取现场投票与网络投票相结 合的方式。 3、会议召开地点：湖北省荆门市杨湾路 122 号公司会议室。 特别提示： 4、会议召集人：公司董事会。 5、 ...

上海市锦天城（武汉）律师事务所 关于湖北亨迪药业股份有限公司 二○二五年第二次临时股东大会的 法律意见书 地址：武汉市江汉区云霞路 187 号民生金融中心 8 层 03-05 电话：027-83828888 邮编：430030 上海市锦天城（武汉）律师事务所 法律意见书 上海市锦天城（武汉）律师事务所 关于湖北亨迪药业股份有限公司 二○二五年第二次临时股东大会的 法律意见书 致：湖北亨迪药业股份有限公司 上海市锦天城（武汉）律师事务所（以下简称"本所"）接受湖北亨迪药业 股份有限公司（以下简称"公司"）委托，委派本律师通过远程视频方式出席公 司二○二五年第二次临时股东大会（以下简称"本次股东大会"）。本律师根据《中 华人民共和国公司法》（以下简称《公司法》）等法律、法规、规章和其他规范性 文件以及《湖北亨迪药业股份有限公司章程》（以下简称《公司章程》）的有关规 定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核 ...

Core Viewpoint - Hendi Pharmaceutical has obtained the drug registration certificate for Ibuprofen suspension from the National Medical Products Administration as of June 2025, and is currently preparing for product launch and sales [1] Company Developments - The company is actively working on the preliminary preparations for the product's market launch following the receipt of the registration certificate [1] - The impact of the product registration on the company's operating performance is not expected to be significant in the short term [1] Market Considerations - Future revenue generation from the product is uncertain due to factors such as non-uniqueness of the product, competition from similar products, and the effectiveness of the company's business promotion and sales scale [1]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Methoclopramide Hydrochloride [2] Group 1 - The approval is for the chemical raw material drug Methoclopramide Hydrochloride [2]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Methoclopramide Hydrochloride, a dopamine receptor antagonist used to alleviate nausea and vomiting symptoms, as well as to promote gastrointestinal motility to improve dyspepsia and delayed gastric emptying [1] Company Summary - Hendi Pharmaceutical (301211.SZ) has recently announced the approval of its application for Methoclopramide Hydrochloride [1] - The drug is primarily indicated for the relief of nausea and vomiting [1] - Additionally, it can aid in enhancing gastrointestinal motility, addressing issues such as dyspepsia and delayed gastric emptying [1]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Methoclopramide Hydrochloride, a dopamine receptor antagonist used to alleviate nausea and vomiting symptoms, as well as to promote gastrointestinal motility to improve dyspepsia and delayed gastric emptying [1] Company Summary - Hendi Pharmaceutical (301211) announced the receipt of the approval notice for Methoclopramide Hydrochloride from the National Medical Products Administration [1] - The drug is primarily indicated for the relief of nausea and vomiting [1] - Additionally, it can aid in enhancing gastrointestinal motility, addressing issues such as dyspepsia and delayed gastric emptying [1]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Methochlorpromazine Hydrochloride, a dopamine receptor antagonist used to alleviate nausea and vomiting symptoms, as well as to promote gastrointestinal motility for improving dyspepsia and delayed gastric emptying [1] Company Summary - Hendi Pharmaceutical (301211.SZ) has announced the approval of Methochlorpromazine Hydrochloride, indicating a significant milestone in its product development pipeline [1] - The drug is primarily indicated for the treatment of nausea and vomiting, which could enhance the company's portfolio in the gastrointestinal therapeutic area [1] Industry Summary - The approval of Methochlorpromazine Hydrochloride reflects ongoing regulatory support for new pharmaceutical products in the market, highlighting the importance of innovative treatments for common gastrointestinal issues [1] - The use of dopamine receptor antagonists in managing gastrointestinal symptoms underscores the growing demand for effective therapies in this segment [1]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Metoclopramide Hydrochloride, a dopamine receptor antagonist used to alleviate nausea and vomiting symptoms, as well as to promote gastrointestinal motility to improve dyspepsia and delayed gastric emptying [1] Company Summary - Hendi Pharmaceutical (301211.SZ) has announced the receipt of a marketing approval notification for Metoclopramide Hydrochloride [1] - The drug is primarily indicated for the relief of nausea and vomiting [1] - Additionally, it can aid in enhancing gastrointestinal motility, addressing issues such as dyspepsia and delayed gastric emptying [1]

证券代码：301211 证券简称：亨迪药业 公告编号：2025-041 湖北亨迪药业股份有限公司 关于获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 湖北亨迪药业股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的关于盐酸甲氧氯普胺（以下简称"药品"）的《化学原料药上 市申请批准通知书》（证书编号：2025YS00820）。现将有关情况公告如下： 一、药品的基本情况 药品名称：盐酸甲氧氯普胺 登记号：Y20230001040 规格：12kg/桶 四、风险提示 由于医药产品的销售受国家政策、市场需求、同类型药品市场竞争等因素的 影响，未来该产品销售情况存在不确定性，敬请广大投资者谨慎决策，注意防范 投资风险。 生产企业：湖北亨迪药业股份有限公司 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 二、药品的其他相关情况 盐酸甲氧氯普胺是一种多巴胺受体拮抗剂，主要用于缓解恶心、呕 ...